肠内沙丁胺醇对急性颈段脊髓损伤后心动过缓事件的影响
该回顾性研究纳入2016年1月1日至2017年12月31日在一级创伤中心ICU收治的58例急性颈段脊髓损伤患者,评估肠内沙丁胺醇治疗心动过缓的安全性和可行性。沙丁胺醇启动时间为伤后1.5±1.7天,疗程9.3±4.5天,日均剂量7.8±4.5 mg。心动过缓发生于136/766患者日(17%),高血糖(1%)和心动过速(3%)少见,无低钾血症发生。多因素分析显示女性(P=0.006)和ASIA分级A、B或C(P<0.001)与心动过缓风险升高相关,而沙丁胺醇剂量(P=0.009)和去甲肾上腺素使用(P=0.008)与心动过缓风险降低相关。作者认为肠内沙丁胺醇安全可行且呈剂量依赖性降低心动过缓发生,但需进一步前瞻性试验。
要点
- 58例急性颈段脊髓损伤患者中,肠内沙丁胺醇启动时间为伤后1.5±1.7天,疗程9.3±4.5天,日均剂量7.8±4.5 mg。
- 心动过缓(心率<60次/分)发生于136/766患者日(17%),高血糖(1%)和心动过速(心率>100次/分,3%)少见,无低钾血症。
- 多因素分析:女性(P=0.006)和ASIA分级A、B或C(P<0.001)与心动过缓风险升高独立相关。
- 多因素分析:沙丁胺醇剂量(P=0.009)和去甲肾上腺素使用(P=0.008)与心动过缓风险降低独立相关。
- 作者认为肠内沙丁胺醇安全可行且呈剂量依赖性降低心动过缓发生,但需进一步前瞻性试验验证。
适用人群与场景
- 急性颈段脊髓损伤并收入一级创伤中心ICU的患者。
- 排除标准:伤前单纯使用β受体阻滞剂、同时使用起搏器、年龄小于18岁或年龄大于75岁。
- 所有患者按标准治疗在伤后前7天进行平均动脉压(MAP)提升,目标为大于85 mm Hg。
诊断标准与关键阈值
- 心动过缓定义为心率小于60次/分(bpm)。
- 心动过速定义为心率大于100次/分(bpm)。
- MAP目标为大于85 mm Hg(伤后前7天)。
处置流程与药物剂量
- 肠内沙丁胺醇:启动时间为伤后1.5±1.7天,疗程9.3±4.5天,日均剂量7.8±4.5 mg(肠内给药)。
- 所有患者按标准治疗在伤后前7天进行MAP提升,目标大于85 mm Hg。
研究设计与关键结果
- 回顾性研究,纳入2016年1月1日至2017年12月31日在一级创伤中心ICU收治的58例急性颈段脊髓损伤患者(年龄45±18岁,76%男性)。
- 肠内沙丁胺醇启动时间伤后1.5±1.7天,疗程9.3±4.5天,日均剂量7.8±4.5 mg。
- 心动过缓发生于136/766患者日(17%);高血糖发生率1%,心动过速发生率3%,无低钾血症发生。
- 多因素广义估计方程分析:女性(P=0.006)和ASIA分级A、B或C(P<0.001)与心动过缓风险升高独立相关;沙丁胺醇剂量(P=0.009)和去甲肾上腺素使用(P=0.008)与心动过缓风险降低独立相关。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性;作者指出需进一步前瞻性试验验证肠内沙丁胺醇在脊髓损伤后的应用。
对床旁实践的改变
- 作者认为肠内沙丁胺醇在急性颈段脊髓损伤中是安全可行的治疗心动过缓的方法,鉴于未观察到高血糖、低钾血症或心动过速等显著副作用。
- 作者认为肠内沙丁胺醇耐受良好,且呈剂量依赖性与心动过缓发生减少相关。
- 作者建议需进一步开展前瞻性试验验证肠内沙丁胺醇在脊髓损伤后的应用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute cervical spinal cord injury (ACSCI) is commonly complicated by spinal shock, resulting in hemodynamic instability characterized by bradycardia and hypotension that can have fatal consequences. Current guidelines recommend the use of intravenous beta and dopamine agonists, such as norepinephrine and dopamine, respectively. We sought to determine whether enteral albuterol would be a safe and feasible treatment for bradycardia without an increase in the occurrence of known side effects of albuterol in patients with ACSCI.
METHODS: A retrospective review of patients with ACSCI admitted to an intensive care unit at a level I trauma center and treated with enteral albuterol was conducted. Patients were excluded for the following reasons: pure beta blocker use prior to injury, concurrent use of pacemaker, age of less than 18 years, or age more than 75 years. As part of the standard of care, all patients underwent mean arterial pressure (MAP) augmentation to reach a goal of greater than 85 mm Hg during the first 7 days post injury. All eligible patient charts were reviewed for demographic characteristics, daily minimum and maximum heart rate and MAP, and concomitant vasoactive medication use. Bradycardia and tachycardia were defined as heart rate less than 60 beats per minute (bpm) and greater than 100 bpm, respectively. Factors found to be associated with bradycardia on univariate analysis were entered into a multivariable generalized estimating equation analysis to determine factors independently associated with bradycardia during the study period.
RESULTS: There were 58 patients with cervical ASCI (age 45 ± 18 years, 76% men) admitted between January 1, 2016, and December 31, 2017, that met the study criteria. The mean time to initiation of albuterol was 1.5 ± 1.7 days post injury, with a duration of 9.3 ± 4.5 days and a mean daily dosage of 7.8 ± 4.5 mg. Bradycardia was observed in 136 of 766 patient days (17%). There were a few episodes of hyperglycemia (1%) and tachycardia (3%), but no episodes of hypokalemia. In a multivariable analysis, female sex (P = 0.006) and American Spinal Cord Injury Association grade A, B, or C (P < 0.001) were associated with a higher risk of developing bradycardia, whereas dosage of albuterol (P = 0.009) and norepinephrine use (P = 0.008) were associated with a lower risk of developing bradycardia.
CONCLUSIONS: Albuterol administration in ASCI is a safe and feasible treatment for bradycardia, given that no significant side effects, such as hyperglycemia, hypokalemia, or tachycardia, were observed. The administration of enteral albuterol was well tolerated and, in a dose-dependent manner, associated with a lower occurrence of bradycardia. Further prospective trials for the use of enteral albuterol after SCI are warranted.
参考来源
- Lim-Hing K, Massetti J, Pajoumand M, et al. Impact of Enteral Albuterol on Bradycardic Events After Acute Cervical Spinal Cord Injury. Neurocrit Care. 2021. PMID: 34845597. doi:10.1007/s12028-021-01384-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。